基礎LH 太低, 誘導排卵反應可能不佳
(baseline circulating LH <0.5 IU/L, <2 IU/L and <5 IU/L were associated with a 39.1%, 25.2% and 13.6% risk, respectively)
Hum Reprod
. 2019 Oct 2;34(10):2027-2035. doi: 10.1093/humrep/dez132.
Predicting Suboptimal Oocyte Yield Following GnRH Agonist Trigger by Measuring Serum LH at the Start of Ovarian Stimulation
B Popovic-Todorovic 1, S Santos-Ribeiro 1 2, P Drakopoulos 1, M De Vos 1, A Racca 1, S Mackens 1, Y Thorrez 1, G Verheyen 1, H Tournaye 1, L Quintero 3, C Blockeel 1
Affiliations expand
PMID: 31560740 DOI: 10.1093/humrep/dez132
Abstract
Study question: Are the LH levels at the start of ovarian stimulation predictive of suboptimal oocyte yield from GnRH agonist triggering in GnRH antagonist down-regulated cycles?
Summary answer: LH levels at the start of ovarian stimulation are an independent predictor of suboptimal oocyte yield following a GnRH agonist trigger.
What is known already: A GnRH agonist ovulation trigger may result in an inadequate oocyte yield in a small subset of patients. This failure can range from empty follicle syndrome to the retrieval of much fewer oocytes than expected. Suboptimal response to a GnRH agonist trigger has been defined as the presence of circulating LH levels <15 IU/l 12 h after triggering. It has been shown that patients with immeasurable LH levels on trigger day have an up to 25% risk of suboptimal response.
Study design, size, duration: In this retrospective cohort study, all patients (n = 3334) who received GnRH agonist triggering (using Triptoreline 0.2 mg) for final oocyte maturation undergoing a GnRH antagonist cycle in our centre from 2011 to 2017 were included. The primary outcome of the study was oocyte yield, defined as the ratio between the total number of collected oocytes and the number of follicles with a mean diameter >10 mm prior to GnRH agonist trigger.
Participants/materials, setting, methods: The endocrine profile of all patients was studied at initiation as well as at the end of ovarian stimulation. In order to evaluate whether LH levels, not only at the end but also at the start, of ovarian stimulation predicted oocyte yield, we performed multivariable regression analysis adjusting for the following confounding factors: female age, body mass index, oral contraceptives before treatment, basal and trigger day estradiol levels, starting FSH levels, use of highly purified human menopausal gonadotrophin and total gonadotropin dose. Suboptimal response to GnRH agonist trigger was defined as <10th percentile of oocyte yield.
Main results and the role of chance: The average age was 31.9 years, and the mean oocyte yield was 89%. The suboptimal response to GnRH agonist trigger cut-off (<10th percentile) was 45%, which was exhibited by 340 patients. Following confounder adjustment, multivariable regression analysis showed that LH levels at the initiation of ovarian stimulation remained an independent predictor of suboptimal response even in the multivariable model (adjusted OR 0.920, 95% CI 0.871-0.971). Patients with immeasurable LH levels at the start of stimulation (<0.1 IU/l) had a 45.2% risk of suboptimal response, while the risk decreased with increasing basal LH levels; baseline circulating LH <0.5 IU/L, <2 IU/L and <5 IU/L were associated with a 39.1%, 25.2% and 13.6% risk, respectively.
2020年6月21日
2020年6月19日
捐卵卵子染色體狀況不會受到高齡受卵母體影響
J Assist Reprod Genet
. 2019 Oct;36(10):2039-2045. doi: 10.1007/s10815-019-01549-z. Epub 2019 Aug 5.
Advanced Paternal Age Does Not Affect Embryo Aneuploidy Following Blastocyst Biopsy in Egg Donor Cycles
Robert J Carrasquillo 1 2, Taylor P Kohn 3, Cengiz Cinnioglu 4, Carmen Rubio 5, Carlos Simon 5, Ranjith Ramasamy 6, Nasser Al-Asmar 5
Affiliations expand
PMID: 31385121 PMCID: PMC6823410 (available on 2020-10-01) DOI: 10.1007/s10815-019-01549-z
Free PMC article
Abstract
Purpose: To study the impact of advanced paternal age on embryo aneuploidy.
Methods: This is a multicenter international retrospective case series of couples undergoing assisted reproduction via in vitro fertilization using donor eggs to control for maternal factors and preimplantation genetic testing for aneuploidy via next-generation sequencing at Igenomix reproductive testing centers. The main outcome measure was the prevalence of embryo aneuploidy in egg donor cycles. Semen analysis data was retrieved for a small subset of the male patients.
Results: Data from 1202 IVF/ICSI egg donor cycles using ejaculated sperm (total 6934 embryos) evaluated using PGT-A between January 2016 and April 2018 in a global population across all Igenomix centers were included. No significant association was identified between advancing paternal age and the prevalence of embryo aneuploidy overall and when analyzing for each chromosome. There was also no significant association between advancing paternal age and specific aneuploid conditions (monosomy, trisomy, partial deletion/duplication) for all chromosomes in the genome.
Conclusions: This is the largest study of its kind in an international patient population to evaluate the impact of advancing paternal age on embryo aneuploidy. We conclude there is no specific effect of paternal age on the prevalence of embryo aneuploidy in the context of embryo biopsies from egg donor cycles.
J Assist Reprod Genet
. 2019 Oct;36(10):2039-2045. doi: 10.1007/s10815-019-01549-z. Epub 2019 Aug 5.
Advanced Paternal Age Does Not Affect Embryo Aneuploidy Following Blastocyst Biopsy in Egg Donor Cycles
Robert J Carrasquillo 1 2, Taylor P Kohn 3, Cengiz Cinnioglu 4, Carmen Rubio 5, Carlos Simon 5, Ranjith Ramasamy 6, Nasser Al-Asmar 5
Affiliations expand
PMID: 31385121 PMCID: PMC6823410 (available on 2020-10-01) DOI: 10.1007/s10815-019-01549-z
Free PMC article
Abstract
Purpose: To study the impact of advanced paternal age on embryo aneuploidy.
Methods: This is a multicenter international retrospective case series of couples undergoing assisted reproduction via in vitro fertilization using donor eggs to control for maternal factors and preimplantation genetic testing for aneuploidy via next-generation sequencing at Igenomix reproductive testing centers. The main outcome measure was the prevalence of embryo aneuploidy in egg donor cycles. Semen analysis data was retrieved for a small subset of the male patients.
Results: Data from 1202 IVF/ICSI egg donor cycles using ejaculated sperm (total 6934 embryos) evaluated using PGT-A between January 2016 and April 2018 in a global population across all Igenomix centers were included. No significant association was identified between advancing paternal age and the prevalence of embryo aneuploidy overall and when analyzing for each chromosome. There was also no significant association between advancing paternal age and specific aneuploid conditions (monosomy, trisomy, partial deletion/duplication) for all chromosomes in the genome.
Conclusions: This is the largest study of its kind in an international patient population to evaluate the impact of advancing paternal age on embryo aneuploidy. We conclude there is no specific effect of paternal age on the prevalence of embryo aneuploidy in the context of embryo biopsies from egg donor cycles.
胚胎粒線體DNA含量或變動無法有效評估D3或D5胚胎染色體狀況
mtDNA Dynamics Between Cleavage-Stage Embryos and Blastocysts
Methods: A retrospective single-centre descriptive study was performed between August 2016 and January 2017. Forty patients, with 112 embryos, undergoing preimplantation genetic testing for aneuploidies (PGT-A) by next-generation sequencing (NGS) were included. Embryos that reached the blastocyst stage and were not selected for fresh embryo transfer were included following consecutive biopsies of a single blastomere on day 3 and trophectoderm biopsy of day 5 blastocysts.
Results: Cleavage-stage mtDNA was significantly lower in fast cleaving embryos (p = 0.016). Based on the concordance between day 3 and day 5 biopsies, a difference was identified in blastocyst mtDNA content between groups (p = 0.019); true euploid blastocysts presented a lower mtDNA content. No association was identified between cleavage-stage mtDNA content and ploidy status (OR 1.008 [0.981-1.036], p = 0.565) nor between blastocyst mtDNA content and ploidy outcome (OR 0.954 [0.898-1.014], p = 0.129). No difference was found when comparing mtDNA content and ploidy outcome between the two reproductive age groups (p = 0.505 (cleavage stage) and p = 0.774 (blastocyst)).
Conclusion: Mitochondrial DNA content of cleavage-stage embryos and blastocysts is unable to predict ploidy status. Subgroup analysis based on ploidy concordance between day 3 and day 5 revealed a significantly lower mtDNA content for true euploid blastocysts. Reproductive ageing does not affect mtDNA content.
2020年6月13日
鮮胚植入後失敗後，可考慮改為全凍胚解凍植入
Freeze-all Can Be a Superior Therapy to Another Fresh Cycle in Patients With Prior Fresh Blastocyst Implantation Failure
Bruce S Shapiro 1, Said T Daneshmand 2, Forest C Garner 2, Martha Aguirre 3, Cynthia Hudson 3 Reprod Biomed Online. 2014 Sep;29(3):286-90. doi: 10.1016/j.rbmo.2014.04.009. Epub 2014 May 14.
Implantation failure has various causes, including impaired uterine receptivity following ovarian stimulation. This retrospective cohort study compared outcomes in patients with prior implantation failure who elected to undergo another fresh cycle versus those who opted for embryo cohort cryopreservation (freeze-all) and subsequent thaw. There were 269 patients with implantation failure following fresh autologous blastocyst transfer opting to undergo a subsequent cycle, with 163 choosing another fresh cycle and 106 electing freeze-all and subsequent thaw. Multiple logistic regression analysis indicated that cohort cryopreservation was associated with greater chance of live birth when compared with another fresh cycle (P < 0.0001). The odds ratio for live birth with freeze-all relative to a fresh cycle was 3.8 (95% CI 2.1-7.2). A second analysis was then performed using cumulative live birth rate as the outcome measure. Multiple logistic regression indicated freeze-all was associated with greater cumulative live birth rate than was a fresh cycle (OR 1.9, 95% CI 1.1-3.3, P = 0.0287). These findings suggest that, following implantation failure with fresh blastocysts, patients have a significantly greater chance of live birth with freeze-all and subsequent thaw than with another fresh cycle.
Freeze-all Can Be a Superior Therapy to Another Fresh Cycle in Patients With Prior Fresh Blastocyst Implantation Failure
Bruce S Shapiro 1, Said T Daneshmand 2, Forest C Garner 2, Martha Aguirre 3, Cynthia Hudson 3 Reprod Biomed Online. 2014 Sep;29(3):286-90. doi: 10.1016/j.rbmo.2014.04.009. Epub 2014 May 14.
Implantation failure has various causes, including impaired uterine receptivity following ovarian stimulation. This retrospective cohort study compared outcomes in patients with prior implantation failure who elected to undergo another fresh cycle versus those who opted for embryo cohort cryopreservation (freeze-all) and subsequent thaw. There were 269 patients with implantation failure following fresh autologous blastocyst transfer opting to undergo a subsequent cycle, with 163 choosing another fresh cycle and 106 electing freeze-all and subsequent thaw. Multiple logistic regression analysis indicated that cohort cryopreservation was associated with greater chance of live birth when compared with another fresh cycle (P < 0.0001). The odds ratio for live birth with freeze-all relative to a fresh cycle was 3.8 (95% CI 2.1-7.2). A second analysis was then performed using cumulative live birth rate as the outcome measure. Multiple logistic regression indicated freeze-all was associated with greater cumulative live birth rate than was a fresh cycle (OR 1.9, 95% CI 1.1-3.3, P = 0.0287). These findings suggest that, following implantation failure with fresh blastocysts, patients have a significantly greater chance of live birth with freeze-all and subsequent thaw than with another fresh cycle.
PGT若無正常胚胎 可考慮植入染色體鑲嵌胚胎
Should Every Embryo Undergo Preimplantation Genetic Testing for Aneuploidy? A Review of the Modern Approach to in Vitro Fertilization
Susan M Maxwell 1, James A Grifo 2
Clin Obstet Gynaecol. 2018 Nov;53:38-47.
Aneuploid conceptions constitute the majority of pregnancy failures in women of advanced maternal age. The best way to combat age-related decline in fertility is through preimplantation genetic testing for aneuploidy (PGT-A). PGT-A allows for better embryo selection, which improves implantation rates with single embryo transfer and reduces miscarriage rates. Single embryo transfers decrease multiple gestations and adverse pregnancy outcomes such as preterm or low birth weight infants. Advancements in extended embryo culture, blastocyst biopsy techniques, and 24-chromosome aneuploidy screening platforms have made PGT-A safe and accessible for all patients who undergo in vitro fertilization. Improved genomic coverage of new sequencing platforms, such as next-generation sequencing, has increased the identification and diagnosis of mosaicism and partial aneuploidies in preimplantation embryos. Mosaic embryos have decreased viability compared to euploid embryos when transferred, but some mosaic embryos result in normal live births. Whole genome amplification artifacts may contribute to a misdiagnosis of mosaicism, or some mosaic embryos may self-correct to euploid after implantation. For this reason, patients without euploid embryos should be given the option of transferring mosaic embryos after genetic counseling. Further research is needed to characterize which mosaic embryos may be viable.
Should Every Embryo Undergo Preimplantation Genetic Testing for Aneuploidy? A Review of the Modern Approach to in Vitro Fertilization
Susan M Maxwell 1, James A Grifo 2
Clin Obstet Gynaecol. 2018 Nov;53:38-47.
Aneuploid conceptions constitute the majority of pregnancy failures in women of advanced maternal age. The best way to combat age-related decline in fertility is through preimplantation genetic testing for aneuploidy (PGT-A). PGT-A allows for better embryo selection, which improves implantation rates with single embryo transfer and reduces miscarriage rates. Single embryo transfers decrease multiple gestations and adverse pregnancy outcomes such as preterm or low birth weight infants. Advancements in extended embryo culture, blastocyst biopsy techniques, and 24-chromosome aneuploidy screening platforms have made PGT-A safe and accessible for all patients who undergo in vitro fertilization. Improved genomic coverage of new sequencing platforms, such as next-generation sequencing, has increased the identification and diagnosis of mosaicism and partial aneuploidies in preimplantation embryos. Mosaic embryos have decreased viability compared to euploid embryos when transferred, but some mosaic embryos result in normal live births. Whole genome amplification artifacts may contribute to a misdiagnosis of mosaicism, or some mosaic embryos may self-correct to euploid after implantation. For this reason, patients without euploid embryos should be given the option of transferring mosaic embryos after genetic counseling. Further research is needed to characterize which mosaic embryos may be viable.
2020年6月9日
PGT胚胎染色體異常胚胎植入仍可順利懷孕 顯示胚胎具有自我修復之功能
Worldwide Live Births Following the Transfer of Chromosomally "Abnormal" Embryos After PGT/A: Results of a Worldwide Web-Based Survey
Pasquale Patrizio 1, Gon Shoham 2, Zeev Shoham 3 4, Milton Leong 5, David H Barad 6 7, Norbert Gleicher 6 7 8 9
J Assist Reprod Genet 2019 Aug;36(8):1599-1607. doi: 10.1007/s10815-019-01510-0. Epub 2019 Jun 24.
Purpose: Preimplantation genetic testing for aneuploidy (PGT-A) has become increasingly controversial since normal euploid births have been reported following transfer of embryos diagnosed as "abnormal." There is an increasing trend in transferring "abnormal" embryos; but it is still unknown how many IVF centers transfer "abnormal" embryos and with what efficiency.
Methods: We performed a worldwide web-survey of IVF centers to elucidate PGT-A related practice patterns including transfer of human embryos found "abnormal" by PGT-A. Participating centers reflected in vitro fertilization (IVF) cycles in the USA, Canada, Europe, Asia, South America, and Africa.
Results: One hundred fifty-one IVF centers completed the survey; 125 (83%) reported utilization of PGT-A. Europe had the highest utilization (32.3%), followed by the USA and Canada combined at 29.1%. The leading indications for PGT-A were advanced maternal age (77%), followed by recurrent implantation failure (70%), unexplained pregnancy loss (65%), and sex determination (25%); 14% of respondents used PGT-A for all of their IVF cycles; 20% of IVF units reported transfers of chromosomally "abnormal" embryos, and 56% of these took place in the USA, followed by Asia in 20%. Remarkably, 106 (49.3%) cycles resulted in ongoing pregnancies (n = 50) or live births (n = 56). Miscarriages were rare (n = 20; 9.3%).
Conclusions: The transfers of "abnormal" embryos by PGT-A offered robust pregnancy and live birth chances with low miscarriage rates. These data further strengthen the argument that PGT-A cannot reliably determine which embryos should or should not be transferred and leads to disposal of many normal embryos with excellent pregnancy potential.
Worldwide Live Births Following the Transfer of Chromosomally "Abnormal" Embryos After PGT/A: Results of a Worldwide Web-Based Survey
Pasquale Patrizio 1, Gon Shoham 2, Zeev Shoham 3 4, Milton Leong 5, David H Barad 6 7, Norbert Gleicher 6 7 8 9
J Assist Reprod Genet 2019 Aug;36(8):1599-1607. doi: 10.1007/s10815-019-01510-0. Epub 2019 Jun 24.
Purpose: Preimplantation genetic testing for aneuploidy (PGT-A) has become increasingly controversial since normal euploid births have been reported following transfer of embryos diagnosed as "abnormal." There is an increasing trend in transferring "abnormal" embryos; but it is still unknown how many IVF centers transfer "abnormal" embryos and with what efficiency.
Methods: We performed a worldwide web-survey of IVF centers to elucidate PGT-A related practice patterns including transfer of human embryos found "abnormal" by PGT-A. Participating centers reflected in vitro fertilization (IVF) cycles in the USA, Canada, Europe, Asia, South America, and Africa.
Results: One hundred fifty-one IVF centers completed the survey; 125 (83%) reported utilization of PGT-A. Europe had the highest utilization (32.3%), followed by the USA and Canada combined at 29.1%. The leading indications for PGT-A were advanced maternal age (77%), followed by recurrent implantation failure (70%), unexplained pregnancy loss (65%), and sex determination (25%); 14% of respondents used PGT-A for all of their IVF cycles; 20% of IVF units reported transfers of chromosomally "abnormal" embryos, and 56% of these took place in the USA, followed by Asia in 20%. Remarkably, 106 (49.3%) cycles resulted in ongoing pregnancies (n = 50) or live births (n = 56). Miscarriages were rare (n = 20; 9.3%).
Conclusions: The transfers of "abnormal" embryos by PGT-A offered robust pregnancy and live birth chances with low miscarriage rates. These data further strengthen the argument that PGT-A cannot reliably determine which embryos should or should not be transferred and leads to disposal of many normal embryos with excellent pregnancy potential.
卵巢退化未必黃體期不足
Association Between Diminished Ovarian Reserve and Luteal Phase Deficiency
Abbey Pfister 1, Natalie M Crawford 2, Anne Z Steiner 3
Fertil Steril 2019 Aug;112(2):378-386. doi: 10.1016/j.fertnstert.2019.03.032. Epub 2019 May 2.
Objective: To determine the association between biomarkers of ovarian reserve and luteal phase deficiency (LPD).
Patient(s): Women attempting conception, aged 30-44 years, without known infertility.
Intervention(s): Measurement of early follicular phase serum levels of antimüllerian hormone, FSH, inhibin B, and E2.
Main outcome measure(s): The primary outcome was LPD, defined by luteal bleeding (LB) (≥1 day of LB) or a short luteal phase length (≤11 days).
Result(s): Overall, 755 women provided information on 2,171 menstrual cycles and serum for measurement of at least one biomarker of ovarian reserve. There were 2,096 cycles from 754 women in the LB cohort, of which 40% experienced LB. After adjusting for age, race, previous miscarriages, and previous pregnancies, diminished ovarian reserve (DOR) was not significantly associated with LB. Low early follicular phase FSH levels increased the odds of LB (odds ratio [OR] 1.84; 95% confidence interval [CI] 1.25-2.71), as did high early follicular phase E2 levels (OR 1.59; 95% CI 1.26-2.01). A total of 608 cycles from 286 women were included in the analysis of luteal phase length, of which 13% had a short luteal phase. After adjusting for age, there was no significant association between DOR and a short luteal phase. The risk of a short luteal phase decreased with increasing inhibin B (OR 0.61; 95% CI 0.45-0.81).
Conclusion(s): Although DOR is not associated with LPD, hormone dysfunction in the early follicular phase may contribute to LPD in women of older reproductive age.
Association Between Diminished Ovarian Reserve and Luteal Phase Deficiency
Abbey Pfister 1, Natalie M Crawford 2, Anne Z Steiner 3
Fertil Steril 2019 Aug;112(2):378-386. doi: 10.1016/j.fertnstert.2019.03.032. Epub 2019 May 2.
Objective: To determine the association between biomarkers of ovarian reserve and luteal phase deficiency (LPD).
Patient(s): Women attempting conception, aged 30-44 years, without known infertility.
Intervention(s): Measurement of early follicular phase serum levels of antimüllerian hormone, FSH, inhibin B, and E2.
Main outcome measure(s): The primary outcome was LPD, defined by luteal bleeding (LB) (≥1 day of LB) or a short luteal phase length (≤11 days).
Result(s): Overall, 755 women provided information on 2,171 menstrual cycles and serum for measurement of at least one biomarker of ovarian reserve. There were 2,096 cycles from 754 women in the LB cohort, of which 40% experienced LB. After adjusting for age, race, previous miscarriages, and previous pregnancies, diminished ovarian reserve (DOR) was not significantly associated with LB. Low early follicular phase FSH levels increased the odds of LB (odds ratio [OR] 1.84; 95% confidence interval [CI] 1.25-2.71), as did high early follicular phase E2 levels (OR 1.59; 95% CI 1.26-2.01). A total of 608 cycles from 286 women were included in the analysis of luteal phase length, of which 13% had a short luteal phase. After adjusting for age, there was no significant association between DOR and a short luteal phase. The risk of a short luteal phase decreased with increasing inhibin B (OR 0.61; 95% CI 0.45-0.81).
Conclusion(s): Although DOR is not associated with LPD, hormone dysfunction in the early follicular phase may contribute to LPD in women of older reproductive age.
飲用咖啡對於IVF懷孕率無明顯影響
Impact of Female Daily Coffee Consumption on Successful Fertility Treatment: A Danish Cohort Study
Julie Lyngsø 1, Ulrik Schiøler Kesmodel 2, Bjørn Bay 3, Hans Jakob Ingerslev 4, Anne-Marie Nybo Andersen 5, Cecilia Høst Ramlau-Hansen 6
Fertil Steril. 2019 Jul;112(1):120-129.e2. doi: 10.1016/j.fertnstert.2019.03.014. Epub 2019 Apr 28.
Objective: To investigate whether female coffee consumption affects the chance of achieving a clinical pregnancy and a live birth among women and couples receiving medically assisted reproduction (MAR) treatment.
Patient(s): A total of 1,708 women and potential partners undergoing fertility treatment, contributing with 1,511 intrauterine insemination (IUI) cycles, 2,870 in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) cycles, and 1,355 frozen embryo transfer cycles.
Main outcome measure(s): Clinical pregnancy and live birth in consecutive treatment cycles in the Danish national health registries, enabling complete follow-up, and estimation of the cumulative chance of live birth for three consecutive treatment cycles.
Result(s): Among women receiving IVF or ICSI treatment, coffee consumption did not seem to affect the chance of achieving a clinical pregnancy and a live birth. Women treated with IUI who had a daily coffee consumption of 1-5 cups were more likely to achieve a clinical pregnancy (adjusted relative risk 1.49; 95% confidence interval, 1.05-2.11) and live birth (adjusted relative risk 1.53; 95% confidence interval, 1.06-2.21) compared with the reference group of coffee abstainers.
Conclusion(s): Women consuming 1-5 cups versus none had a 1.5-fold higher probability of achieving a pregnancy or a live birth when receiving IUI. No associations were found, however, between women's daily coffee consumption and achieving a pregnancy or a live birth from IVF/ICSI.
Impact of Female Daily Coffee Consumption on Successful Fertility Treatment: A Danish Cohort Study
Julie Lyngsø 1, Ulrik Schiøler Kesmodel 2, Bjørn Bay 3, Hans Jakob Ingerslev 4, Anne-Marie Nybo Andersen 5, Cecilia Høst Ramlau-Hansen 6
Fertil Steril. 2019 Jul;112(1):120-129.e2. doi: 10.1016/j.fertnstert.2019.03.014. Epub 2019 Apr 28.
Objective: To investigate whether female coffee consumption affects the chance of achieving a clinical pregnancy and a live birth among women and couples receiving medically assisted reproduction (MAR) treatment.
Patient(s): A total of 1,708 women and potential partners undergoing fertility treatment, contributing with 1,511 intrauterine insemination (IUI) cycles, 2,870 in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) cycles, and 1,355 frozen embryo transfer cycles.
Main outcome measure(s): Clinical pregnancy and live birth in consecutive treatment cycles in the Danish national health registries, enabling complete follow-up, and estimation of the cumulative chance of live birth for three consecutive treatment cycles.
Result(s): Among women receiving IVF or ICSI treatment, coffee consumption did not seem to affect the chance of achieving a clinical pregnancy and a live birth. Women treated with IUI who had a daily coffee consumption of 1-5 cups were more likely to achieve a clinical pregnancy (adjusted relative risk 1.49; 95% confidence interval, 1.05-2.11) and live birth (adjusted relative risk 1.53; 95% confidence interval, 1.06-2.21) compared with the reference group of coffee abstainers.
Conclusion(s): Women consuming 1-5 cups versus none had a 1.5-fold higher probability of achieving a pregnancy or a live birth when receiving IUI. No associations were found, however, between women's daily coffee consumption and achieving a pregnancy or a live birth from IVF/ICSI.
訂閱：
文章 (Atom)